MX2010012010A - Quinolinas y analogos relacionados como moduladores de sirtuin. - Google Patents

Quinolinas y analogos relacionados como moduladores de sirtuin.

Info

Publication number
MX2010012010A
MX2010012010A MX2010012010A MX2010012010A MX2010012010A MX 2010012010 A MX2010012010 A MX 2010012010A MX 2010012010 A MX2010012010 A MX 2010012010A MX 2010012010 A MX2010012010 A MX 2010012010A MX 2010012010 A MX2010012010 A MX 2010012010A
Authority
MX
Mexico
Prior art keywords
alkyl
phenyl
sirtuin
substituted
fluoro
Prior art date
Application number
MX2010012010A
Other languages
English (en)
Spanish (es)
Inventor
Charles A Blum
Jeremy S Disch
Chi B Vu
Robert B Perni
Stephanie K Springer
Original Assignee
Sirtris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirtris Pharmaceuticals Inc filed Critical Sirtris Pharmaceuticals Inc
Publication of MX2010012010A publication Critical patent/MX2010012010A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
MX2010012010A 2008-05-01 2009-04-30 Quinolinas y analogos relacionados como moduladores de sirtuin. MX2010012010A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12611208P 2008-05-01 2008-05-01
PCT/US2009/042255 WO2009134973A1 (en) 2008-05-01 2009-04-30 Quenolines and related analogs as sirtuin modulators

Publications (1)

Publication Number Publication Date
MX2010012010A true MX2010012010A (es) 2010-11-30

Family

ID=41255415

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010012010A MX2010012010A (es) 2008-05-01 2009-04-30 Quinolinas y analogos relacionados como moduladores de sirtuin.

Country Status (15)

Country Link
US (1) US8685970B2 (enExample)
EP (1) EP2273992B1 (enExample)
JP (1) JP5425891B2 (enExample)
KR (1) KR20110007235A (enExample)
CN (1) CN102083438B (enExample)
AU (1) AU2009243006B2 (enExample)
BR (1) BRPI0912356A2 (enExample)
CA (1) CA2723135A1 (enExample)
EA (1) EA021938B1 (enExample)
ES (1) ES2586459T3 (enExample)
IL (1) IL208997A0 (enExample)
MX (1) MX2010012010A (enExample)
SG (1) SG190603A1 (enExample)
WO (1) WO2009134973A1 (enExample)
ZA (1) ZA201007677B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104193740A (zh) 2008-07-03 2014-12-10 西特里斯药业公司 作为沉默调节蛋白调节剂的苯并咪唑类和相关的类似物
RU2519779C2 (ru) 2008-09-29 2014-06-20 Сертрис Фармасьютикалз Инк. Хиназолинон, хинолон и родственные аналоги в качестве модуляторов сиртуина
WO2010093808A1 (en) * 2009-02-11 2010-08-19 Reaction Biology Corp. Selective kinase inhibitors
MX2011009213A (es) * 2009-03-02 2011-12-14 Sirtris Pharmaceuticals Inc Quinolinas 8-sustituidas y analogos relacionados como moduladores de sirtuina.
JP2013509442A (ja) 2009-10-29 2013-03-14 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン調節因子としての二環式ピリジンおよび類似体
CN101723894B (zh) * 2009-12-03 2011-12-28 南京大学 N-喹啉酰胺类衍生物及其制法与用途
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
WO2012122534A2 (en) 2011-03-10 2012-09-13 The Trustees Of Columbia University In The City Of New York N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2855459B1 (en) * 2012-05-31 2020-04-29 F.Hoffmann-La Roche Ag Aminoquinazoline and pyridopyrimidine derivatives
EP2882746B1 (en) 2012-08-07 2016-12-07 Merck Patent GmbH Pyridopyrimidine derivatives as protein kinase inhibitors
ES2718550T3 (es) 2013-05-13 2019-07-02 Glaxosmithkline Llc Análogos de urea con puente sustituidos como moduladores de sirtuinas
WO2016081692A2 (en) * 2014-11-19 2016-05-26 Glaxosmithkline Llc Substituted bridged urea analogs as sirtuin modulators
US10207995B2 (en) * 2013-06-13 2019-02-19 Monsanto Technology Llc Acetyl CoA carboxylase modulators
US9844218B2 (en) 2013-06-13 2017-12-19 Monsanto Technology Llc Acetyl-CoA carboxylase modulators
JP2017518306A (ja) 2014-06-02 2017-07-06 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 結晶性β−Ｄ−ニコチンアミドリボシドの製造および使用
KR20170008320A (ko) 2014-06-06 2017-01-23 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 니코틴아미드 리보시드 유사체 및 그의 제약 조성물 및 용도
US20200347038A1 (en) 2014-08-29 2020-11-05 Russell Dahl Quinolines that modulate serca and their use for treating disease
WO2016032569A1 (en) * 2014-08-29 2016-03-03 Celladon Corporation Quinolines and their use for treating endoplasmic reticulum stress-caused diseases
KR102662215B1 (ko) 2014-11-06 2024-05-02 비알 - 알&디 인베스트먼츠, 에스.에이. 치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
WO2016073891A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
WO2017091681A1 (en) 2015-11-24 2017-06-01 Aclaris Therapeutics, Inc. Selective kinase inhibitors
US10383868B2 (en) * 2015-11-28 2019-08-20 Russell Dahl Quinoline containing compounds and their use for treating endoplasmic reticulum stress-related diseases
DK3386591T3 (da) 2015-12-09 2020-09-28 Cadent Therapeutics Inc Heteroaromatic nmda receptor modulators and uses thereof
WO2017100593A1 (en) 2015-12-09 2017-06-15 Luc Therapeutics Thienopyrimidinone nmda receptor modulators and uses thereof
WO2017176961A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US11192892B2 (en) 2016-04-06 2021-12-07 Bial—R&D Investments, S.A. Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders
JP7034935B2 (ja) 2016-04-06 2022-03-14 リソソーマル・セラピューティクス・インコーポレイテッド ピロロ［１，２－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
US11345698B2 (en) 2016-05-05 2022-05-31 Bial—R&D Investments, S.A. Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
US20190389865A1 (en) * 2016-05-05 2019-12-26 Lysosomal Therapeutics Inc. SUBSTITUTED PYRROLO[1,2-a]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2017192930A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
JP7058256B2 (ja) 2016-07-14 2022-04-21 ブリストル－マイヤーズ スクイブ カンパニー 二環式ヘテロアリール置換化合物
ES2823127T3 (es) 2016-07-14 2021-05-06 Bristol Myers Squibb Co Compuestos tricíclicos de quinolina y azaquinolina sustituidos con heteroarilo como inhibidores de PAR4
CN109689649B (zh) 2016-07-14 2022-07-19 百时美施贵宝公司 经二环杂芳基取代的化合物
US11274107B2 (en) 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
CA3073051A1 (en) * 2017-08-17 2019-02-21 Ikena Oncology, Inc. Ahr inhibitors and uses thereof
WO2019057053A1 (zh) * 2017-09-20 2019-03-28 北京加科思益新药研发有限公司 用作fgfr4抑制剂的稠环衍生物
CA3090150A1 (en) 2018-02-06 2019-08-15 Ideaya Biosciences, Inc. Ahr modulators
HUE062566T2 (hu) 2018-08-03 2023-11-28 Novartis Ag Heteroaromás NMDA receptor modulátorok és alkalmazásaik
CN113101295A (zh) * 2020-03-20 2021-07-13 上海疆云医疗健康科技有限公司 二苯乙烯类似物在治疗糖尿病肾脏疾病中的用途
US11730729B2 (en) 2020-07-20 2023-08-22 Neurodon Corporation Quinolines that modulate SERCA and their use for treating disease
KR20230146012A (ko) * 2021-02-09 2023-10-18 셀진 코포레이션 연충 감염 및 질병의 치료를 위한 설폰아미드 및 이들의용도
CN112939955B (zh) * 2021-03-05 2022-10-21 朗捷睿(苏州)生物科技有限公司 一种8-(吡啶酰胺)取代香豆素类化合物及其制备方法和应用
AU2022380979A1 (en) 2021-11-02 2024-06-06 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof
WO2024026423A1 (en) * 2022-07-27 2024-02-01 Black Diamond Therapeutics, Inc. Substituted quinoline derivatives as pi3k inhibitors

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5838449B2 (ja) * 1979-04-17 1983-08-23 カネボウ株式会社 微粉末状絹フィプロインの製造法
NZ212525A (en) * 1985-06-24 1989-02-24 Dfc New Zealand Ltd Formerly D Nitrogen-containing heterocyclic compounds, and pharmaceutical compositions containing such
JP2002363169A (ja) 2001-06-08 2002-12-18 Fujiyakuhin Co Ltd 抗腫瘍活性を有する複素環化合物
JP2004043457A (ja) * 2002-05-22 2004-02-12 Kyorin Pharmaceut Co Ltd ２−置換キノリン−８−カルボン酸アミド誘導体
FR2864535B1 (fr) * 2003-12-24 2006-12-22 Merck Sante Sas Derives acides de quinoline et leurs applications en therapeutique
GB0428475D0 (en) * 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
EP1853610A1 (en) 2005-03-03 2007-11-14 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
WO2006094210A2 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Tetrahydroquinoxalinone sirtuin modulators
WO2006094239A2 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fluorescence polarization assays for acetyltransferase/deacetylase activity
WO2006094233A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N,n'-dicyclic isothiourea sirtuin modulators
WO2006094248A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Aryl-substituted cyclic sirtuin modulators
WO2006094209A2 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N-benzimidazolylalkyl-substituted amide sirtuin modulators
CA2599992A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Acridine and quinoline dervatives as sirtuin modulators
WO2006094246A2 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N-arylmethyl benzamide sirtuin modulators
EP1877054A2 (en) 2005-03-30 2008-01-16 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20070014833A1 (en) 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
WO2006127987A2 (en) 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
EP1899332A1 (en) 2005-06-24 2008-03-19 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c.
AU2006269459B2 (en) 2005-07-07 2013-02-07 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
ES2397275T3 (es) 2005-08-04 2013-03-05 Sirtris Pharmaceuticals, Inc. Derivados de imidazopiridina como agentes moduladores de la sirtuína
US7855289B2 (en) * 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) * 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) * 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
ES2389111T3 (es) 2005-12-02 2012-10-23 Sirtris Pharmaceuticals, Inc. Ensayos de espectrometría de masas para la actividad acetiltransferasa/desacetilasa
AU2006339607A1 (en) 2005-12-02 2007-09-13 Sirtris Pharmaceuticals, Inc. Modulators of Cdc2-like kinases (Clks) and methods of use thereof
US20080021063A1 (en) * 2006-07-18 2008-01-24 Kazantsev Aleksey G Compositions and methods for modulating sirtuin activity
WO2008027379A2 (en) 2006-08-29 2008-03-06 Sirtris Pharmaceuticals, Inc. Indicators of sirtuin activity and methods of use thereof
US20080249103A1 (en) 2006-11-15 2008-10-09 Sirtris Pharmaceuticals, Inc. Sirtuin polymorphisms and methods of use thereof
WO2008073451A2 (en) 2006-12-11 2008-06-19 Sirtris Pharmaceuticals, Inc. Benzoimidazole derivatives as sirtuin (sir) modulating compounds
WO2008100423A1 (en) 2007-02-09 2008-08-21 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
WO2008100376A2 (en) 2007-02-15 2008-08-21 Sirtris Pharmaceuticals, Inc. Truncation variants of sirt1 and methods of use thereof
AU2008229385A1 (en) 2007-03-19 2008-09-25 Sirtris Pharmaceuticals, Inc. Biomarkers of sirtuin activity and methods of use thereof
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
TW200918542A (en) * 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
WO2009058348A1 (en) 2007-11-01 2009-05-07 Sirtris Pharmaceuticals, Inc. Amide derivatives as sirtuin modulators
CN101910184A (zh) 2007-11-08 2010-12-08 西特里斯药业公司 可溶性噻唑并吡啶
WO2009085226A2 (en) 2007-12-21 2009-07-09 Sirtris Pharmaceuticals, Inc. Inhibitors of cdc2-like kinases (clks) and methods of use thereof
EP2249806A2 (en) 2008-01-08 2010-11-17 Sirtris Pharmaceuticals, Inc. Resveratrol formulations
US20110113498A1 (en) 2008-05-15 2011-05-12 Westphal Christoph H Sirt1 polymorphic variants and methods of use thereof
JP2011521960A (ja) 2008-05-29 2011-07-28 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン調節薬としてのイミダゾピリジンおよび関連する類似体
CN104193740A (zh) 2008-07-03 2014-12-10 西特里斯药业公司 作为沉默调节蛋白调节剂的苯并咪唑类和相关的类似物
AU2009282076A1 (en) 2008-08-12 2010-02-18 Sirtris Pharmaceuticals, Inc. Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators
RU2519779C2 (ru) 2008-09-29 2014-06-20 Сертрис Фармасьютикалз Инк. Хиназолинон, хинолон и родственные аналоги в качестве модуляторов сиртуина
BRPI0919625A2 (pt) 2008-10-29 2015-12-01 Sirtris Pharmaceutical Inc piriridina, piridina bicíclica e análogos relacionados como moduladores de sirtuína
CA2746221A1 (en) 2008-12-08 2010-07-08 Sirtris Pharmaceuticals, Inc. Isoindolinone and related analogs as sirtuin modulators
US20130190309A1 (en) 2008-12-16 2013-07-25 Chi B. Vu Phthalazinone and related analogs as sirtuin modulators
CN102388054B (zh) 2008-12-19 2015-03-04 西特里斯药业公司 噻唑并吡啶沉默调节蛋白调节剂的化合物
WO2010088574A1 (en) 2009-01-30 2010-08-05 Sirtris Pharmaceuticals, Inc. Azabenzimidazoles and related analogs as sirtuin modulators
MX2011009213A (es) 2009-03-02 2011-12-14 Sirtris Pharmaceuticals Inc Quinolinas 8-sustituidas y analogos relacionados como moduladores de sirtuina.
WO2011116176A1 (en) 2010-03-17 2011-09-22 Sirtris Pharmaceuticals Inc. 3-substitued imidazo (4, 5-b) pyridines and analogs as sirtuin modulators

Also Published As

Publication number Publication date
WO2009134973A8 (en) 2010-12-16
US8685970B2 (en) 2014-04-01
AU2009243006B2 (en) 2013-03-21
AU2009243006A1 (en) 2009-11-05
US20110046110A1 (en) 2011-02-24
EP2273992A4 (en) 2011-10-05
ZA201007677B (en) 2011-09-28
EP2273992A1 (en) 2011-01-19
BRPI0912356A2 (pt) 2015-10-06
ES2586459T3 (es) 2016-10-14
JP2011519863A (ja) 2011-07-14
EA201071263A1 (ru) 2011-06-30
CN102083438B (zh) 2016-11-09
EP2273992B1 (en) 2016-05-25
SG190603A1 (en) 2013-06-28
CA2723135A1 (en) 2009-11-05
KR20110007235A (ko) 2011-01-21
WO2009134973A1 (en) 2009-11-05
CN102083438A (zh) 2011-06-01
JP5425891B2 (ja) 2014-02-26
EA021938B1 (ru) 2015-10-30
IL208997A0 (en) 2011-01-31

Similar Documents

Publication Publication Date Title
AU2009243006B2 (en) Quinolines and related analogs as sirtuin modulators
EP2344475B1 (en) Quinazolinone, quinolone and related analogs as sirtuin modulators
US20110263564A1 (en) Pyridine, bicyclic pyridine and related analogs as sirtuin modulators
CA2754058A1 (en) 8-substituted quinolines and related analogs as sirtuin modulators
AU2009333543A1 (en) Isoindolinone and related analogs as sirtuin modulators
EP2315763A1 (en) Benzimidazoles and related analogs as sirtuin modulators
WO2009146358A1 (en) Imidazopyridine and related analogs as sirtuin modulators
EP2373646A1 (en) Phthalazinone and related analogs as sirtuin modulators
CA2733966A1 (en) Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators
WO2011116176A1 (en) 3-substitued imidazo (4, 5-b) pyridines and analogs as sirtuin modulators
WO2010088574A1 (en) Azabenzimidazoles and related analogs as sirtuin modulators

Legal Events

Date Code Title Description
FA Abandonment or withdrawal